MedTrace Logo

Study to Evaluate the Efficacy and Safety of Moxifloxacin Versus Amoxicillin/Clavulanate in the Treatment of Acute Bacterial Rhinosinusitis

NCT00493038 · Status: TERMINATED · Phase: PHASE4 · Type: INTERVENTIONAL · Enrollment: 293

Last updated 2014-11-07

Study results available
· View outcomes & findings →

Summary

This is a clinical study organized to collect clinical data to better define the activity of some antimicrobials already marketed in Italy and in the rest of the world for the treatment of acute bacterial rhinosinusitis

Conditions

Interventions

DRUG

Moxifloxacin (Avelox, BAY12-8039)

Patients will be administered daily a single moxifloxacin 400 mg tablet for 7 days

DRUG

Amoxicillin/Clavulanate

Patient will be administered daily Amoxicilline/Clavulanate 1000 mg tablets every 8 hours for 10 days

Sponsors & Collaborators

Principal Investigators

  • Bayer Study Director · Bayer

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-02-28
Primary Completion
2008-01-31
Completion
2008-01-31

Countries

  • Italy

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00493038 on ClinicalTrials.gov